Crossmark

A preclinical animal study of a novel, simple, and secure duct and vessel occluder for laparoscopic surgery

Crossref DOI link: https://doi.org/10.1007/s00464-018-6052-0

Published Online: 2018-01-16

Published Print: 2018-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Szold, Amir

Miller, Arnold https://orcid.org/0000-0003-2697-4762
Lilach, Nir

Botero-Anug, Ana-Maria

Miller, Raanan

Schwaitzberg, Steven D.
License Information

Text and Data Mining valid from 2018-01-16
More Information

Article History

Received: 1 August 2017

Accepted: 11 January 2018

First Online: 16 January 2018

Compliance with ethical standards

:

: This study is fully funded by Amsel Medical Corporation, a private company registered in Delaware, USA. Amir Szold, MD, Medical Director, Assia Medical Group, Assuta Medical Center, Tel Aviv, Israel—consultant surgeon to Amsel Medical and advisor to LifeBond, Asymmetric Medical, Augmedix Medical, Virtual Ports, MST Medical, and CMO of Human Extensions. Arnold Miller, M.D.—vascular surgeon, founder, and president of Amsel Medical Corporation. Nir Lilach, I.E.D.—consultant engineer (Eliachar Technologies Development Ltd, Haifa, Israel). Ana-Maria Botero-Anug, D.V.M., D.V.Sc—consultant pathologist (Pathovet, Rechovot, Israel). Raanan Miller Ph.D.—founder and C.E.O. of Amsel Medical Corporation. Steven Schwaitzberg—Chairman, Department of Surgery, University at Buffalo. Dr Schwaitzberg is on the medical advisory panels for Amsel Medical Corporation, Acuity Bio, Arch Therapeutics, Gordian, and Human Extensions.